{"id":2232,"date":"2017-07-25T17:13:02","date_gmt":"2017-07-25T11:43:02","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2232"},"modified":"2021-07-24T12:56:48","modified_gmt":"2021-07-24T07:26:48","slug":"notizia-48","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-48","title":{"rendered":"Remicade\u2019s launch; Endo cuts jobs; Analysts downgrade Pfizer; Corning $500M glass project"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a0d038d415cf\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a0d038d415cf\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-48\/#Samsung_and_Merck_launch_Remicade_biosim_at_35_discount\" >Samsung and Merck launch Remicade biosim at 35% discount<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-48\/#Endo_cuts_875_more_jobs_by_closing_Alabama_manufacturing_site\" >Endo cuts 875 more jobs by closing Alabama manufacturing site<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-48\/#With_Viagra_and_Lyrica_fading_analysts_downgrade_Pfizer_due_to_mounting_challenges\" >With Viagra and Lyrica fading, analysts downgrade Pfizer due to mounting challenges<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-48\/#Corning_plans_500M_pharma_glass_project_that_Trump_announced\" >Corning plans $500M pharma glass project that Trump announced<\/a><\/li><\/ul><\/nav><\/div>\n<h3><span class=\"ez-toc-section\" id=\"Samsung_and_Merck_launch_Remicade_biosim_at_35_discount\"><\/span>Samsung and Merck launch Remicade biosim at 35% discount<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">After the first biosimilar of Johnson &amp; Johnson\u2019s big-selling immunology drug Remicade hit the market last year at a modest discount, another has come along with a much deeper pricing slash. Samsung and marketing partner Merck &amp; Co. Monday launched their Renflexis in the U.S. at a 35% markdown to the blockbuster J&amp;J anti-inflammatory med. Their move follows last year\u2019s launch by Pfizer for its version, Inflectra, at a 15% discount. The prices are before negotiated rebates. As J&amp;J\u2019s top-selling med, Remicade brought in nearly $5 billion in the U.S. last year. With those critical sales under threat, the company has moved to defend its superstar in court and elsewhere.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Endo_cuts_875_more_jobs_by_closing_Alabama_manufacturing_site\"><\/span>Endo cuts 875 more jobs by closing Alabama manufacturing site<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Endo has decided that the 350 jobs it whacked from its Huntsville, Alabama, manufacturing site last year were not nearly enough. The drugmaker said it will close operations there instead, cutting 875 more jobs. \u00a0Endo will take pretax restructuring charges of approximately $325 million and expects to see between $55 million and $65 million in annual net pretax cost savings by Q4 2018. About 840 remaining employees will lose their jobs. The 875 in cuts include 35 positions that have been left unfilled. The plant had employed about 1,250 until last year when Endo laid off about 350 employees.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"With_Viagra_and_Lyrica_fading_analysts_downgrade_Pfizer_due_to_mounting_challenges\"><\/span>With Viagra and Lyrica fading, analysts downgrade Pfizer due to mounting challenges<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Having failed twice to complete an inversion in recent years, Pfizer is a bit of a precarious position. On Friday, the firm downgraded its rating for the pharma giant, citing a few weak points in its business going forward. ED drug Viagra is coming off patent later this year, while nerve pain treatment Lyrica will follow at the end of next year. Sales for blockbuster pneumococcal vaccine Prevnar 13 are on a slide, and breast cancer med Ibrance\u2019s growth is slowing. Together, Viagra and Lyrica brought in $4.2 billion in the U.S. last year. Knowing all of this, Pfizer has made moves to \u201cboost its inorganic growth\u201d through takeouts of Anacor and Medivation, but drugs brought in from those moves won\u2019t offset existing problems, according to Credit Suisse.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Corning_plans_500M_pharma_glass_project_that_Trump_announced\"><\/span>Corning plans $500M pharma glass project that Trump announced<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">U.S. manufacturer Corning said it is time the pharmaceutical industry has new, more durable glass for its new injected medicines, and with input and commitments from Pfizer and Merck &amp; Co., it intends to produce it in the U.S. Its plan to make an initial investment of $500 million and hire 1,000 employees was made by President Trump at the White House as part of his \u201cMade in America\u201d events this week. \u201cThis initiative will bring a key industry to our shores which for too long has been dominated by foreign countries,\u201d Trump said, explaining that 98% of the industry is currently overseas. That investment includes expanding Corning facilities in Corning, New York, and Vineland, New Jersey, and building a new manufacturing plant at a yet to be disclosed location in the Southeast. Eventually, Corning could invest up to $4 billion and hire up to 4,000 new employees, it said Thursday.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Samsung and Merck launch Remicade biosim at 35% discount After the first biosimilar of Johnson &amp; Johnson\u2019s big-selling immunology drug Remicade hit the market last year at a modest discount, another has come along with a much deeper pricing slash. Samsung and marketing partner Merck &amp; Co. Monday launched their Renflexis in the U.S. at [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1534,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[134,204,17555,386,395,460,712,639,2731,595,17556],"industry":[17225],"therapeutic_areas":[17227,17557,17245],"class_list":["post-2232","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-business-consultant","tag-delveinsight","tag-lyrica","tag-market-trends","tag-merck","tag-pfizer","tag-pharma-industry","tag-pharma-news","tag-samsung","tag-usfda","tag-viagra","industry-pharmaceutical","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-male-health","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Remicade&#039;s biosimilar; Endo closes plant; Corning&#039;s project; Pfizer&#039;s loss<\/title>\n<meta name=\"description\" content=\"After the first biosimilar of Johnson &amp; Johnson\u2019s big-selling immunology drug Remicade hit the market last year at a modest discount...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-48\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Remicade&#039;s biosimilar; Endo closes plant; Corning&#039;s project; Pfizer&#039;s loss\" \/>\n<meta property=\"og:description\" content=\"After the first biosimilar of Johnson &amp; Johnson\u2019s big-selling immunology drug Remicade hit the market last year at a modest discount...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-48\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-07-25T11:43:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/11\/04164451\/notizie-su-misura.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"282\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Remicade's biosimilar; Endo closes plant; Corning's project; Pfizer's loss","description":"After the first biosimilar of Johnson & Johnson\u2019s big-selling immunology drug Remicade hit the market last year at a modest discount...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-48","og_locale":"en_US","og_type":"article","og_title":"Remicade's biosimilar; Endo closes plant; Corning's project; Pfizer's loss","og_description":"After the first biosimilar of Johnson & Johnson\u2019s big-selling immunology drug Remicade hit the market last year at a modest discount...","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-48","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-07-25T11:43:02+00:00","article_modified_time":"2021-07-24T07:26:48+00:00","og_image":[{"width":640,"height":282,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/11\/04164451\/notizie-su-misura.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-48","url":"https:\/\/www.delveinsight.com\/blog\/notizia-48","name":"Remicade's biosimilar; Endo closes plant; Corning's project; Pfizer's loss","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-48#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-48#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/11\/04164451\/notizie-su-misura.jpg","datePublished":"2017-07-25T11:43:02+00:00","dateModified":"2021-07-24T07:26:48+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"After the first biosimilar of Johnson & Johnson\u2019s big-selling immunology drug Remicade hit the market last year at a modest discount...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-48"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-48#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/11\/04164451\/notizie-su-misura.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/11\/04164451\/notizie-su-misura.jpg","width":640,"height":282},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/11\/04164451\/notizie-su-misura-300x132.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Business Consultant<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Lyrica<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">market trends<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Merck<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pharma Industry<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">SAMSUNG<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">USFDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Viagra<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Business Consultant<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Lyrica<\/span>","<span class=\"advgb-post-tax-term\">market trends<\/span>","<span class=\"advgb-post-tax-term\">Merck<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">Pharma Industry<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">SAMSUNG<\/span>","<span class=\"advgb-post-tax-term\">USFDA<\/span>","<span class=\"advgb-post-tax-term\">Viagra<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jul 25, 2017","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jul 25, 2017 5:13 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2232","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2232"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2232\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1534"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2232"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2232"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2232"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2232"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2232"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}